FibroBiologics, Inc. (FBLG)
1.36
-0.07
(-4.90%)
USD |
NASDAQ |
Sep 21, 16:00
1.32
-0.04
(-2.94%)
After-Hours: 20:00
FibroBiologics Debt to Equity Ratio : 0.3154 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.3154 |
| March 31, 2026 | 0.9531 |
| December 31, 2025 | 0.3915 |
| September 30, 2025 | 56.90 |
| June 30, 2025 | 12.53 |
| March 31, 2025 | 3.028 |
| December 31, 2024 | 3.858 |
| September 30, 2024 | 0.5707 |
| Date | Value |
|---|---|
| June 30, 2024 | -0.7692 |
| March 31, 2024 | -0.5457 |
| December 31, 2023 | 1.394 |
| September 30, 2023 | 0.1708 |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | -1.883 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
| Vericel Corp. | 0.2556 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 7.929M |
| Total Liabilities (Quarterly) | 3.293M |
| Shareholders Equity (Quarterly) | 4.636M |
| Current Ratio | 2.644 |
| Net Debt Paydown Yield | 19.62% |